Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
– Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies
Immunome Appoints Bob Lechleider, M.D., as Chief Medical Officer
– Seasoned biotechnology executive and board-certified physician in medical oncology joins executive team as Immunome advances growing pipeline of cancer therapies
Venatorx Pharmaceuticals Awarded a Third Antibiotic BARDA Contract
Total award of up to $167 million for development of novel oral antibiotic ceftibuten-ledaborbactam etzadroxil for treatment of complicated urinary tract infection (cUTI), including pyelonephritis
Immunome and Morphimmune Announce Successful Completion of Merger with $125 Million PIPE to Develop Novel Targeted Cancer Therapies
– Clay B. Siegall, Ph.D., former co-founder & CEO of Seagen, Inc., appointed as Chairman and CEO
– $125 million private placement investment completed with leading institutional investors will support cash runway expected to extend into Q1 2026*
– Expected to submit three investigational new drug applications (INDs) within 18 months
ImmunoGenesis Doses First Patient in Phase 1a/1b Clinical Trial of IMGS-001 in Relapsed or Refractory Advanced Solid Tumors
IMGS-001 is the first dual-specific PD-L1/PD-L2 antibody with cytotoxic function designed to treat immune-excluded cancers that are resistant to existing immunotherapies
SIRPant Immunotherapeutics to Present Trial in Progress Poster at the Society for Immunotherapy of Cancer 38th Annual Meeting
Venatorx Pharmaceuticals to Present at IDWeek 2023
– New data to be presented from Phase 3 CERTAIN-1 study with Cefepime-Taniborbactam
– MD Anderson Cancer Center analysis of Cefepime-Taniborbactam in vitro activity against clinically significant gram-negative bacteria isolated from patients with cancer
Strados Labs Announces Pediatric Asthma Study to Validate its Wearable Device in Children with Wheeze
Strados Labs’ RESP™ Biosensor is currently being used in a clinical trial at Lurie Children’s to determine if the technology can accurately detect wheezing and other symptoms of asthma exacerbation in children.
Relmada Therapeutics Announces Efficacy and Safety Results from the Phase 3 LongTerm Study of REL-1017 in Major Depressive Disorder
Patients newly treated with REL-1017 for up to one year experienced rapid, clinically meaningful, and sustained improvements in depressive symptoms and associated functional impairment
Long-term dosing with REL-1017 was well-tolerated, with low rates of adverse events and discontinuations due to adverse events, and no new safety signals were detected
KayoThera, Inc. Nominates First-in-Class, Oral Inhibitor of the Retinoid Pathway in Genetically Defined Oncology Indications as a Development Candidate
Unique safety profile positions KAYO-1609 as the first retinoid pathway inhibitor to enter Investigational New Drug (IND)-enabling studies
Company expects to file IND application with the U.S. Food & Drug Administration (FDA) by the end of 2024